Results from an expanded phase 1 trial of botensilimab (BOT), a multifunctional anti-CTLA-4, plus balstilimab (BAL; anti-PD-1) for metastatic heavily pretreated microsatellite stable colorectal cancer (MSS CRC)

被引：13

作者：

Bullock, A. ^{[1
]}

Fakih, M. ^{[2
]}

Gordon, M. ^{[3
]}

Tsimberidou, A. ^{[4
]}

El-Khoueiry, A. ^{[5
]}

Wilky, B. ^{[6
]}

Pimentel, A. ^{[7
]}

Margolin, K. ^{[8
]}

Mahadevan, D. ^{[9
]}

Balmanoukian, A. ^{[10
]}

Sanborn, R. ^{[11
]}

Schwartz, G. ^{[12
]}

Abou-Alfa, G. ^{[13
,14
]}

Bockorny, B. ^{[1
]}

Moser, J. ^{[3
]}

Sharma, S. ^{[3
]}

Grossman, J. ^{[15
]}

Rosenthal, K. ^{[15
]}

O'Day, S. ^{[15
]}

Lenz, H. ^{[5
]}

Schlechter, B. ^{[16
]}

机构：

[1] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Boston, MA USA

[2] City Hope Comprehens Canc Ctr, Duarte, CA USA

[3] Honor Hlth TGen, Scottsdale, AZ USA

[4] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[5] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA USA

[6] Univ Colorado, Canc Ctr, Aurora, CO USA

[7] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA

[8] Providence St Johns Canc Inst, Santa Monica, CA USA

[9] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX USA

[10] Angeles Clin & Res Inst, Los Angeles, CA USA

[11] Providence Canc Inst, Earle A Chiles Res Inst, Portland, OR USA

[12] Columbia Univ, Herbert Irving Comprehens Canc Ctr, Med Ctr, New York, NY USA

[13] Cornell Univ, Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA

[14] Cornell Univ, Weill Med Coll, New York, NY USA

[15] Agenus, Lexington, KY USA

[16] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.04.014

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA-4

引用

页码：S178 / S179

页数：2